Acceptability and Nutritional Impact of Double-fortified Salt Containing Iodine and Folic Acid - Phase 1 (DFS-IoFA-1)

March 11, 2025 updated by: University of California, Davis

Evaluation of the Acceptability and Nutritional Impact of Double-fortified Salt Containing Folic Acid and Iodine Among Ethiopian Women of Reproductive Age - Assessment of Women's Nutritional Status and Salt Intakes in the Study Communities

The overarching objective of this two-phase project is to assess the effects of fortifying iodized salt with folic acid on improving women's folate status and thereby reduce the risk of neural tube defects (NTDs), which are highly prevalent in Ethiopia. The project will be conducted in two phases. The purpose of Phase 1, described herein, is to complete formative research in preparation for a community-based, randomized trial, which will be carried out in Phase 2. The objectives of Phase 1 are to: 1) assess the hematological condition and nutritional status with respect to folate, iodine, and other micronutrients among non-pregnant women of reproductive age (WRA) in the study communities, and 2) measure discretionary salt and dietary folate intakes of the women and their households.

Study Overview

Detailed Description

Potentially eligible women of reproductive age (WRA) will be identified from existing community census records and will be listed sequentially. A random number generator will be used to select individual women from this list for possible participation in the Phase 1 studies. In cases where two or more WRA are selected from the same household (HH), one will be randomly selected for possible participation in the study and the other(s) will be replaced by a WRA from another HH, using the same random selection procedure. A member of the study team will then visit the homes of women who are selected for possible participation in Phase 1 to describe the study to them, assess their eligibility, and request their consent to participate. In particular, the data collector will present an initial disclosure statement concerning the screening interview and will then obtain descriptive information from verbally consenting women on their age, general health status, address, cell phone number (if available), and potential willingness to participate in the subsequent research studies. The data collector will review the women's health history and determine their eligibility for the Phase 1 study.

For women who found to be eligible to participate in the Phase 1 study, the field worker will describe the purpose of the study, the study procedures and related risks and benefits, the confidentiality of results, and the fact that participation is voluntary. After providing an opportunity for women to consult with family members and ask any questions to the research team, the field worker (in the presence of a neutral witness) will request written consent from the women to participate in the study. Additional questions will be asked of consenting women regarding their marital status, ethnicity, religion, educational level, and employment; and their housing characteristics (housing construction, water source, sanitary facilities, access to electricity and cell phone service); and selected HH assets.

All eligible, consenting women will be requested to report to the Chefe Donsa Health Center or one of the local health posts within the next one or two days following the initial screening interview for fasting blood collection, anthropometric assessment, additional interviews, and scheduling of subsequent home visits by the study team for full-day dietary observations to measure discretionary salt intake and folate intake and to initiate 24-hour urine collections to measure sodium and iodine excretion. The fasting blood specimens will be collected for a complete blood count and measurement of red blood cell (RBC) folate and serum folate, unmetabolized folic acid, vitamin B12, holo-transcobalamin, methyl malonic acid, other B vitamins, genetic polymorphisms that affect folate metabolism, thyroglobulin, glucose, insulin, retinol binding protein (RBP), ferritin, soluble transferrin receptor, C-reactive protein, and alpha-1 acid glycoprotein and to complete a malaria rapid diagnostic test (RDT). Serum retinol will be measured in a subset of 40 women to establish the relationship between serum retinol and RBP in the study population. Blood specimens may also be collected from a subset of 20 women for possible metabolomics assays and natural killer cell (immune function) assays. Women with a positive RDT and those subsequently found to have anemia (Hb<13.2 g/dL, to adjust for altitude) will be referred to the local health facility for treatment. Additional interviews will be completed to assess the women's birth history, contraceptive use, and household food insecurity.

All women will participate in dietary assessments and 24-hour urine collections on one day within four weeks of enrollment, and a randomly selected sub-set of 40 women will complete these studies on a second day one-to-two weeks later. The purpose of the second set of studies is to allow for calculation of intra-individual variation in intakes and urinary sodium and iodine excretion, which is necessary to estimate the distribution of usual discretionary salt and folate intake and urinary sodium and iodine excretion of the study population. The dietary studies will involve a dietitian who will remain in the participant's home throughout the day to weigh all foods included in mixed dishes and to weigh the amounts served and consumed. Portions of each food will be collected to analyze these in the laboratory for sodium and selected nutrient contents. The investigators The investigators will also carry out HH salt disappearance studies over a period of one week using iodized refined salt provided by the project to determine the rate of salt utilization in relation to HH size. This information will be used to estimate the quantities of salt that we will need to deliver during Phase 2.

Study Type

Observational

Enrollment (Actual)

100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Addis Ababa, Ethiopia
        • Ethiopian Public Health Institute

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 49 years (Adult)

Accepts Healthy Volunteers

N/A

Sampling Method

Probability Sample

Study Population

The study will be conducted in the central highlands of Oromia region in Ethiopia, approximately 2 hours from the capital Addis Ababa.

Description

Inclusion Criteria:

  • Non-pregnant women 18-49 years of age
  • Agree to use salt provided by the study team for the household salt disappearance study
  • Provide written, informed consent.

Exclusion Criteria

  • Currently pregnant
  • Presence of acute or chronic disease (such as diarrhea, febrile illness, or underlying metabolic disorder) that might affect the participant's dietary intake or folate status
  • Currently using medicines (like anticonvulsants and cancer treatments) that affect folate metabolism
  • Medically prescribed restriction of salt intake

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Women of reproductive age
Randomly selected women of reproductive age in study communities.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Folate status
Time Frame: one week
Red blood cell (RBC) folate concentration using a microbiological assay
one week
Iodine status
Time Frame: four weeks
24-hour urinary iodine excretion using the Sandell-Kolthoff color reaction
four weeks
Discretionary salt intake
Time Frame: four weeks
In-home weighed record of dietary intake
four weeks
Household salt utilization
Time Frame: six weeks
One-week difference in weight of salt provided by study team
six weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Kenneth H Brown, MD, University of California, Davis

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 26, 2023

Primary Completion (Actual)

August 15, 2023

Study Completion (Actual)

May 1, 2024

Study Registration Dates

First Submitted

March 3, 2023

First Submitted That Met QC Criteria

March 30, 2023

First Posted (Actual)

March 31, 2023

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

March 11, 2025

Last Verified

March 1, 2025

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Two years after completion of the data collection, the individual participant data (IPD) data sets will become publicly available to other investigators who have specific research questions that can be addressed by the data and that are not already under analysis by the core research team. Researchers who desire to have access to the clinical specimens will be requested to apply for the specimens and to describe the research question(s) they plan to address.

IPD Sharing Time Frame

The study protocol will be submitted for publication prior to initiation of Phase 2. The statistical analysis plans for Phases 1 and 2 will be publicly available prior to the start of the respective analyses. The informed consent documents will be available (in English and Afaan Oromo) after approval by the respective institutional Review Boards (IRBs) at the University of California Davis (UC Davis) and the Ethiopian Public Health Institute (EPHI). The clinical study report will become available once accepted for publication.

IPD Sharing Access Criteria

As indicated above.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe